High levels of innovation and increased productivity are imperatives of the global healthcare industry. To meet this twin demand, Syngene, our custom research organisation and Clinigene, our clinical research company works in partnership with complementary biotechnology and pharmaceutical companies. We believe these partnerships will positively impact all phases of our discovery portfolio. We are also confident that our well-structured alliances will mitigate the risk of discovery and encourage a stimulating environment of continuous knowledge creation.
Biocon, through Syngene and Clinigene, has built remarkable integrated contract research capabilities to support discovery and development, for both small and large molecules.
Leveraging India’ high quality scientific talent pool and sophisticated world class infrastructure at Biocon Park (the country’s largest biotech campus). Syngene and Clinigene have been consistently engaged in creating value for its clients through innovative research and development.
Syngene, Biocon’s contract research organization, has delivered healthy growth driven by expansion of existing client relationships, addition of new customers, a shift towards integrated and higher value added services, and an accelerating contribution from biology and biologics platforms.
Clinigene, Biocon’s clinical development company, has also established itself as an experienced provider of world class, end-to-end clinical and laboratory services. Capitalizing on India’s cost advantage in operations, its scientific knowledge base and its diverse disease and patient population, Clinigene’s compound-to-clinic competencies continue to attract large multinationals and mid-sized pharma / biotech companies for successful collaborations in the area of clinical development.